DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 12%

DiaMedica Therapeutics Inc (NASDAQ:DMAC) traded up 12% during mid-day trading on Thursday . The company traded as high as $4.90 and last traded at $4.75. 141,991 shares changed hands during mid-day trading, an increase of 138% from the average session volume of 59,624 shares. The stock had previously closed at $4.24.

DMAC has been the topic of a number of analyst reports. ValuEngine upgraded shares of DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, September 11th. Zacks Investment Research upgraded DiaMedica Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research report on Friday, June 19th. Finally, Maxim Group reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research note on Thursday, August 13th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $12.44.

The stock has a market cap of $89.01 million, a P/E ratio of -6.09 and a beta of 2.43. The stock’s 50-day moving average is $4.54 and its two-hundred day moving average is $4.70. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.19 and a quick ratio of 10.19.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in DiaMedica Therapeutics by 19.7% in the 1st quarter. BlackRock Inc. now owns 38,373 shares of the company’s stock worth $108,000 after acquiring an additional 6,320 shares during the last quarter. Corriente Advisors LLC purchased a new position in shares of DiaMedica Therapeutics in the second quarter valued at $1,395,000. Stonepine Capital Management LLC bought a new stake in DiaMedica Therapeutics in the first quarter worth $2,311,000. Finally, Bank of New York Mellon Corp purchased a new stake in DiaMedica Therapeutics during the second quarter valued at $93,000. 16.16% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile (NASDAQ:DMAC)

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

See Also: Economic Bubble

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.